Global Women's Health Academy

High-Risk HPV Primary Testing for Cervical Cancer: A Case Presentation

While the prevalence of cervical cancer in the population has decreased over the years, there are still 12,820 new cases and 4,210 deaths estimated...

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    While the prevalence of cervical cancer in the population has decreased over the years, there are still 12,820 new cases and 4,210 deaths estimated in 2017; however, despite this progress, there remains marked uncertainty among healthcare providers regarding the optimal screening strategy for cervical cancer.  While both primary high-risk HPV testing and cotesting approaches are known to be superior to cytology-alone, current evidence suggests that many patients as well as providers continue to favor cytology-based testing annually.  Healthcare providers thus face challenges in integrating cotesting and primary high-risk HPV testing in clinical practice, or choosing one over the other for individual patients. The case presented in this CME activity addresses some of the issues faced by clinicians when selecting cervical cancer screening strategies for their patients.

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, The Omnia-Prova Education Collaborative (TOPEC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TOPEC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:
    Warner K. Huh, MD
    Margaret Cameron Spain Endowed Chair in Obstetrics and Gynecology
    Professor/Division Director of Obstetrics and Gynecology 
    University of Alabama at Birmingham 
    Birmingham, Alabama

    Dr. Huh has disclosed that he is a consultant for Roche Molecular Systems and is on the Scientific Advisory Board for Merck (V503).

    Reviewers/Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Kenneth Brown has nothing to disclose.
    • Barry A. Fiedel, PhD has nothing to disclose.
    • Kia K. Gray, MPH has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Describe the underlying data supporting the FDA decision on high-risk HPV primary testing for cervical cancer screening
    • Describe barriers to adoption of evolving approaches to cervical cancer screening
    • Counsel patients regarding new screening approaches focusing on their risk for cervical cancer
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians, gynecologists, primary care physicians, nurse practitioners, physician assistants, and certified nurse midwives.

  • Accreditation and Credit Designation Statements

    The Omnia-Prova Education Collaborative, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education has a core focus on women's health and the ways in which diseases and conditions impact the female patient. That unique focus has transformed the CME learning environment for healthcare professionals nationwide. We impact thousands of clinicians annually, many of whom return each year for clinical updates and connectivity with regional peers.

  • Commercial Support

    This activity is supported by an independent educational grant from Roche Diagnostics.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of TOPEC and Omnia Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Omnia Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience."

Facebook Comments

Sign-up for the Global Women's Health Academy newsletters.
Comprehensive Women's Health Education.

Better education for a better you.

* Required
Optional